Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
ETD$20.08-0.37(-1.81%)All Three Leading Independent Proxy Advisory Firms Agree Leadership Change Is Desperately Needed at Ethan Allen[7:15:00 PM ET]CTHCF$0.88+0.01(+0.64%)HyProMag USA Pre-Feasibility Study Outlines Future Expansion Options to Quadruple Planned U.S. Rare Earth Magnet Capacity Indicating an Incremental Post-Tax NPV of up to US$2.1 Billion[7:05:00 PM ET]NTRS$169.55+1.63(+0.97%)LeavePlus Appoints Northern Trust as Asset Servicing Provider[7:00:00 PM ET]CLF$13.41-0.49(-3.52%)Cleveland-Cliffs Confirms Full Compliance with Stelco Undertakings[6:53:00 PM ET]FFMFF$0.90-0.08(-7.78%)FireFly makes another significant high-grade copper-gold VMS discovery[6:52:39 PM ET]MHUBF$0.30-0.04(-11.67%)MineHub Announces Financing[6:49:00 PM ET]FHN$23.43-0.01(-0.04%)First Horizon Declares Cash Dividends on Common and Preferred Stock First Horizon Corporation (NYSE: FHN) (or "First Horizon") today announced that its board of directors declared a quarterly cash dividend of $0.17...[6:46:00 PM ET]URI$1,121.90+23.02(+2.09%)United Rentals Announces Pricing of Offering of $700,000,000 of 5.550% Senior Notes due 2029; $800,000,000 of 5.750% Senior Notes due 2031; $1,000,000,000 of 6.200% Senior Notes due 2036[6:35:00 PM ET]LKQ$17.25-0.17(-0.98%)LKQ Corporation (LKQ) Faces Investor Scrutiny Amid Enterprise Resource Planning System Surprises, CEO Departure; Shares Trade Sharply Lower Again – HBSS[6:31:21 PM ET]ELE$15.46-0.42(-2.64%)Elemental Royalty Announces First Close of Royalty and Streaming Portfolio Alongside Upsized US$250M Credit Facility[6:30:00 PM ET]TTGXF$0.120.00(0.00%)Trans Canada Gold Closes Final Tranche of Non-Brokered Private Placement for Gross Proceeds of CDN $2,205,737 and Prepares for Phase 2 Drilling[6:30:00 PM ET]DSGR$35.010.00(0.00%)Distribution Solutions Group Announces Timing for Third Quarter Fiscal Year 2026 Results[6:30:00 PM ET]BLK$1,127.66+9.41(+0.84%)BlackRock® Canada Announces Final October Cash Distributions for the iShares® Premium Money Market ETF[6:30:00 PM ET]FSBC$44.50+0.41(+0.93%)Five Star Bancorp Announces Third Quarter 2026 Results[6:30:00 PM ET]HLLY$2.56+0.07(+2.81%)Holley Performance Brands and Amotiv Form Strategic Collaboration to Expand Brand Reach Across North America, Australia and New Zealand[6:30:00 PM ET]

OMER · NASDAQ

Omeros Corporation

$16.67 +0.10 (+0.60%)

Company overview

Omeros Corporation is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics, as well as orphan indications targeting inflammation, complement-mediated diseases, cancers related to immune system dysfunction, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2), which has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and is in Phase III trials for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), as well as Phase II trials for COVID-19.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.2B
Employees
202
Headquarters
Seattle, WA
Website
omeros.com
CEO
Gregory A. Demopulos
Listed
October 8, 2009
P/E
12.82
Dividend yield
0.00%

Company financials

Revenue
$9.9M
Gross profit
-$1.2M
Operating income
-$105M
EBITDA
-$104M
Net income
$86.2M
EPS
$1.30
Total assets
$286M
Total debt
$311M
Gross margin
-12.39%
Net margin
871.02%
Earnings yield
7.80%

Price chart

6.1210.0513.9717.9021.82
OMER 1D NASDAQ O16.80H16.80L16.37C16.57-0.29 (-1.72%)Vol699.39K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
OMEROmeros Corporation Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER ACCESS Newswire
OMEROmeros Corporation Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PRNewsWire
OMEROmeros Corporation Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER ACCESS Newswire
OMEROmeros Corporation Stock news Omeros (NASDAQ:OMER) Shares Gap Down – Here’s Why Defense World
OMEROmeros Corporation Stock news Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends Benzinga
OMEROmeros Corporation Stock news Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA Business Wire
OMEROmeros Corporation Stock news Omeros (NASDAQ:OMER) Hits New 1-Year High – Should You Buy? Defense World
OMEROmeros Corporation Stock news Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst Benzinga
OMEROmeros Corporation Stock news What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now? Zacks Investment Research
OMEROmeros Corporation Stock news Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy? Zacks Investment Research
OMEROmeros Corporation Stock news Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Brokerages Defense World
OMEROmeros Corporation Stock news Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript Seeking Alpha
OMEROmeros Corporation Stock news Omeros Q2 Earnings Call Highlights MarketBeat
OMEROmeros Corporation Stock news Omeros (OMER) Q2 Earnings and Revenues Beat Estimates Zacks Investment Research
OMEROmeros Corporation Press release Omeros Corporation Reports Second Quarter 2026 Financial Results Business Wire
OMEROmeros Corporation Press release Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 Business Wire
OMEROmeros Corporation Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER GlobeNewsWire
OMEROmeros Corporation Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER Globe News Wire
OMEROmeros Corporation Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER GlobeNewsWire
OMEROmeros Corporation Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PRNewsWire
See more
FAQ

Questions about Omeros Corporation

What does Omeros Corporation do?
Omeros Corporation is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics, as well as orphan indications targeting inflammation, complement-mediated diseases, cancers related to immune system dysfunction, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2), which has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and is in Phase III trials for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), as well as Phase II trials for COVID-19.
What is OMER's market cap?
Omeros Corporation (OMER) is a listed stock with a live quote. The latest market cap on this page is $1.2B.
Where is Omeros Corporation headquartered?
Omeros Corporation is headquartered in Seattle, WA.
How do I get OMER news from the API?
Call GET /v1/news?tickers=OMER. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does OMER news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for OMER, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the OMER price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs